Abbvie Announces U.S. Fda Approval of Subcutaneous Induction Regimen for Skyrizi for Adults with Moderately to Severely Active Crohn's Disease

AbbVie announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely…

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketscreener.com)